Valneva (VALN) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Valneva SE has reported €116.6 million in total revenues for the first nine months of 2024, with a notable turnaround to a €24.7 million net profit, driven by strong product sales and a successful private placement. The company is progressing with the launch of its chikungunya vaccine in Canada and Europe, and anticipates further approvals in Brazil and the UK. With a promising pipeline, including the S4V2 Shigella vaccine candidate, Valneva is poised for growth and strategic expansion.
For further insights into VALN stock, check out TipRanks’ Stock Analysis page.